005690 — Pharmicell Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid CapHigh Flyer

Annual income statement for Pharmicell Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	R2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	51,812	60,182	56,227	64,851	114,062
Cost of Revenue
Gross Profit	23,708	23,820	15,492	21,330	50,677
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	43,949	51,614	53,400	60,029	79,758
Operating Profit	7,863	8,568	2,828	4,822	34,304
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	9,451	5,969	4,732	6,264	34,767
Provision for Income Taxes
Net Income After Taxes	9,451	10,885	3,578	6,331	40,289
Net Income Before Extraordinary Items
Net Income	9,451	10,885	3,578	6,331	40,289
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	9,451	10,885	3,578	6,331	40,289
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	167	185	39.5	104	671
Dividends per Share